MorphoSys Strengthens Patent Position on its Core HuCAL Technology in Europe
MorphoSys AG announced that the European Patent Office has granted a European divisional patent stemming from MorphoSys's base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection for the Company's core technology. The new patent (EP1143006) captures HuCAL's modular design at the DNA level, providing solid product claim protection in Europe.
A first European HuCAL patent, which is now complemented by the new patent, was issued by the European Patent Office in 2002. HuCAL patents have been granted in the United States, Australia and at the European Patent Office. In total, the Company is prosecuting about thirty different proprietary patent families worldwide, which comes in addition to approximately thirty patent families the Company is pursuing in cooperation with its partners.
"This new patent is a further example of the pioneering nature of our proprietary core technology, HuCAL, and provides us with another solid layer of protection in Europe. We will carry on with this process, continuing to build a strong intellectual property portfolio around HuCAL and our other antibody-related technologies," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
